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ABSTRACT:
Progress in the understanding of the molecular and cellular mechanisms of human 
cancer, including human leukemia and lymphomas, has been spurred by cloning 
of fusion genes created by chromosomal translocations or by retroviral insertional 
mutagenesis; a number of oncogenes and tumor suppressors involved in development 
of a number of malignancies have been identified in this manner. The BCR-ABL fusion 
gene, originating in a multipotent hematopoietic stem cell, is the molecular signature 
of chronic myeloid leukemia (CML). Discovery of this fusion gene has led to the 
development of one of the first successful targeted molecular therapies for cancer 
(Imatinib). It illustrates the advances that can result from an understanding of the 
molecular basis of disease. However, there still remain many as yet unidentified 
mutations that may influence the initiation or progression of human diseases. Thus, 
identification and characterization of the mechanism of action of genes that contribute 
to human diseases is an important and opportune area of current research. One 
promising candidate as a potential therapeutic target is Abelson helper integration 
site-1(Ahi-1/AHI-1) that was identified by retroviral insertional mutagenesis in 
murine models of leukemia/lymphomas and is highly elevated in certain human 
lymphoma and leukemia stem/progenitor cells. It encodes a unique protein with a SH3 
domain, multiple SH3 binding sites and a WD40-repeat domain, suggesting that the 
normal protein has novel signaling activities. A new AHI-1-BCR-ABL-JAK2 interaction 
complex has recently been identified and this complex regulates transforming 
activities and drug resistance in CML stem/progenitor cells. Importantly, AHI-1 
has recently been identified as a susceptibility gene involved in a number of brain 
disorders, including Joubert syndrome. Therefore, understanding molecular functions 
of the AHI-1 gene could lead to important and novel insights into disease processes 
involved in specific types of diseases. Ultimately, this knowledge will set the stage 
for translation into new and more effective diagnostic and treatment strategies.
INTRODUCTION
Remarkable progress has been made in the last decade 
in the identification of oncogenes and tumor suppressors 
that are causative to the development of cancer. Many 
of these discoveries resulted from the cloning of fusion 
genes created by translocations that are characteristic of 
human leukemia and lymphomas [1-7]. The BCR-ABL 
fusion gene, associated with the development of chronic 
myeloid leukemia (CML) [1-6], is the prototype of such 
a discovery and has ultimately led to the development of 
one of the first targeted molecular therapies in cancer [4]. 
The revolution in the treatment of CML patients that has 
resulted from the specific and potent targeting of the BCR-
ABL kinase with STI571/Gleevec/Imatinib Mesylate [8-
10] serves as an important reminder of the advances that Oncotarget 2011; 2:  918 - 934 919 www.impactjournals.com/oncotarget
can come from an understanding of the molecular basis 
of  disease.  Retroviral  insertional  mutagenesis  screens 
have been another powerful and complementary strategy 
in  cancer  gene  discovery;  a  number  of  oncogenes  and 
tumor suppressors that play crucial roles in development 
of human cancer and leukemia have been identified in 
this manner [11-15]. Recently, using retroviral-mediated 
insertional mutagenesis to identify genes that collaborate 
with oncogenes and tumor suppressors of the Myc, p53, 
RB, Ras and ABL pathways have resulted in a number of 
new targets for development of novel cancer therapeutics 
[13].  Nevertheless,  specific  molecular  causes  of  many 
cancers  remain  unknown,  along  with  the  mutations 
responsible for a large proportion of human cancers. There 
is growing evidence that leukemogenesis, like the genesis 
of other malignancies, is a multi-step process requiring the 
accumulation of several mutations for the development of 
overt disease. Therefore, continued identification of new 
genes and characterization of the molecular basis of their 
transforming activity is critical to the future development 
of targeted cancer therapies that will be less toxic and 
more effective. 
Ahi-1 (Abelson helper integration site 1) is a novel 
oncogene  commonly  activated  by  provirus  insertional 
mutagenesis in v-abl and myc-induced murine leukemias 
and lymphomas [16]. It encodes a unique protein with a 
SH3 domain, multiple SH3 binding sites and a WD40-
repeat  domain,  suggesting  that  the  normal  protein 
has  novel  signaling  activities.  Ahi-1/AHI-1 transcript 
levels  are  normally  down-regulated  during  both  early 
murine  and  human  hematopoietic  cell  differentiation 
and  are  highly  deregulated  in  certain  human  leukemic 
cells, including leukemic stem cells from patients with 
chronic myeloid leukemia (CML) and leukemic Sezary 
cells  in  cutaneous  T-cell  lymphoma  (CTCL)  [17,  18]. 
Interestingly, overexpression of Ahi-1 alone in primitive 
hematopoietic cells confers a proliferative advantage in 
vitro and induces a lethal leukemia in vivo; these effects 
can be enhanced by BCR-ABL, a fusion oncoprotein that 
plays a major role in the genesis of CML [19]. Importantly, 
a novel AHI-1-BCR-ABL-JAK2 interaction complex has 
recently been identified in CML cells, mediating these 
effects and playing a key role in mediation of tyrosine 
kinase  inhibitor  (TKI)  response/resistance  of  primary 
CML stem/progenitor cells. These findings suggest that 
AHI-1  could  be  a  potential  new  therapeutic  target  in 
CML stem cells, a population highly resistant to current 
TKI therapy and thus causing disease relapse. Moreover, 
mutations in AHI-1 have also been associated with Joubert 
syndrome, an autosomal recessive brain disorder [20-22]. 
Abnormal development and axonal decussation occur in 
individuals with point mutations in AHI-1, particularly 
within  the  WD40-repeat  and  SH3  domains  [22].  Ahi-
1  can  also  interact  with  Huntingtin-associated  protein 
1 (Hap1) to form a stable complex critical for neonatal 
development  and  involved  in  intracellular  trafficking 
[23]. In addition, AHI-1 isoforms and its mutations also 
underlie  other  diseases,  including  Joubert  syndrome-
associated  nephronophthisis  and  autism,  and  metabolic 
syndromes, including type 2 diabetes [18, 19, 22, 24-27]. 
Therefore, it is likely that AHI-1 mutations are critical in 
the development of diseases such as Joubert syndrome 
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Figure 1: Identification of the Ahi-1 gene by provirus insertional mutagenesis in various murine leukemias and 
lymphomas. Schematic diagram of the positions of the Ahi-1 and Myb regions on mouse chromosome 10 within a 120 kbp genomic 
region. Structural organization of the proviruses integrated at the 3’ end of the Ahi-1 gene is indicated in v-abl-induced pre-B lymphomas, 
Myc-induced T-cell lymphomas and Nf-1-induced murine AML. The localization of the proviruses relative to the exons is shown.Oncotarget 2011; 2:  918 - 934 920 www.impactjournals.com/oncotarget
and specific types of human leukemia. Here we provide an 
extensive review of the molecular and cellular functions 
of AHI-1 and its interacting proteins in the regulation of 
normal and disease development since its identification as 
a cooperative oncogene in v-abl-induced murine leukemia 
in 2002 [16]. Also discussed are potential applications 
of  targeting  specific AHI-1  interaction  complexes  as  a 
new therapeutic strategy for treatment of CML and brain 
disorders.
IDENTIFICATION OF AHI-1/AHI-1 GENE BY 
PROVIRUS INSERTIONAL MUTAGENESIS 
IN MURINE LEUKEMIA AND LYMPHOMAS 
Identification of the Ahi-1 gene in v-abl-induced 
mouse pre-B cell lymphoma
The  Ahi-1  (Abelson  helper  integration  site-
1)  locus  was  initially  identified  as  a  common  helper 
provirus  integration  site  in  16%  of  Abelson  murine 
leukemia  virus  (A-MuLV)-induced  pre-B  lymphomas 
(Figure  1)  [28].  A-MuLV  is  a  replication-defective 
murine retrovirus containing the v-abl oncogene which 
is  responsible  for  its  transforming  potential  [29-33]  in 
murine  models  of  leukemia  and  lymphomas. A-MuLV 
requires a non-defective helper MuLV virus to be able 
to replicate both in vitro and in vivo [34]. It was shown 
that the expression of v-abl is not sufficient to induce full 
malignant  transformation  in  several  mouse  strains  and 
that additional genetic events may be required [35, 36]. 
Using  long-range  restriction  mapping,  the Ahi-1  locus 
was  mapped  to  a  position  ~35  kb  downstream  of  the 
c-myb proto-oncogene on mouse chromosome 10 (Figure 
1) [37]. Another MuLV provirus integration site (Mis-2) 
was also mapped to the same region, 160 kb downstream 
of c-myb and ~120 kb downstream of Ahi-1 [38]. It was 
observed that enhanced expression of c-myb in A-MuLV-
induced pre-B-lymphomas harboring a provirus inserted 
within the Ahi-1 locus was not seen [37], suggesting that 
the locus contained another gene (potentially Ahi-1 gene) 
whose dysregulation might be involved in regulation of 
the malignant transformation of hematopoietic cells. In 
addition, the Ahi-1 locus was also the target of provirus 
insertional  mutagenesis  in  14%  of  the  c-myc-induced 
murine T cell leukemia (Figure 1) [39], 5% of the Moloney 
MuLV-induced rat thymomas [38], 11% of the Hoxa9/
Meis1-induced murine acute myeloid leukemia [40] and 
in acute myeloid leukemias arising in Nf1 heterozygous 
Figure 2: A schematic diagram of the mouse Ahi-1 and human AHI-1 (isoforms I-III) proteins. A summary of the structural 
motifs present in the Ahi-1/AHI-1 proteins is shown, including: one SH3 domain (red box), seven WD40 repeats (blue triangles), proline-
rich motifs (PXXP), PEST sequences (green boxes) and tyrosine kinase phosphorylation sites (Y). Human AHI-1 contains an additional 
coiled-coil domain which is absent from the mouse Ahi-1 (purple ovals). AHI-1 isoform II, the shortest isoform, lacks the SH3 domain 
and isoform III, which is still shorter than isoform I, contains additional coding sequences in its C-terminus which are absent from both 
isoform I and II. 
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mice [41]. These findings suggest that the Ahi-1 locus is 
the target of provirus insertional mutagenesis and that its 
deregulation may contribute to multiple types of murine 
leukemia and lymphomas. 
Subsequently, a new gene (Ahi-1) at the site targeted 
by  the  provirus  insertional  mutations  within  the Ahi-1 
locus was then identified using an exon trapping method 
[16].  Most  of  the  proviral  insertions  were  localized  to 
the 3’ end of the Ahi-1 gene in an inverse transcriptional 
orientation,  primarily  near  and  downstream  of  the  last 
exon, although some were found within various introns 
(Figure  1).  Cloning  of  the  Ahi-1  cDNA  showed  that 
it encodes a 1047 amino acid protein with a number of 
interesting  domains  characteristic  of  a  novel  signaling 
protein. 
The structure of Ahi-1/AHI-1 protein 
The  AHI-1/Ahi-1  gene  covers  more  than  200  kb 
in a region of human chromosome 6 and a minimum of 
100 kb on mouse chromosome 10 (Figure 1). Mouse and 
human  Ahi-1/AHI-1  contain  at  least  27  and  33  exons, 
respectively [16]. The 1.3 kb region upstream of the ATG 
start  codon  of  human  AHI-1  shows  baseline  promoter 
activity  and  contains  two  putative  TATA  boxes  and 
several transcription factor binding sites, such as Oct-1 
and c-fos [42]. The Ahi-1/AHI-1 gene is highly conserved 
in  mammals  and  encodes  a  unique  protein  with  a  Src 
homology 3 (SH3) domain, multiple SH3 binding sites and 
multiple WD40-repeats, all known mediators of protein-
protein interaction (Figure 2) [16, 43-46]. SH3 domains 
are often found in proteins containing SH2 domains and 
are known to bind to proline-rich motifs and to mediate 
specific  protein-protein  interactions  [43,  44,  47].  The 
WD40-repeat domain was first identified in the β-subunits 
of  G-proteins  [45].  A  large  number  of  WD40-repeat-
containing proteins have been identified and are known to 
be involved in aspects of cellular metabolism, including 
assembling  and  remodeling  of  chromosomal  proteins 
[45,  46,  48-51]  and  regulating  the  mRNA  processing 
body, including mRNA degradation. They have also been 
implicated in several inherited diseases, such as Cockayne 
syndrome,  Triple-A  syndrome  and  lissencephaly  [51]. 
Interestingly, the Ahi-1/AHI-1 protein is the only protein 
thus far identified to contain both WD40 repeats and a 
SH3 domain. The SH3-binding sites were initially found 
to bind specifically to the SH3 domain of ABL [52]; many 
SH3 domain interacting proteins have been characterized 
as  regulators  of  protein-protein  interactions  involved 
in signal transduction, cell cycle control and malignant 
transformation [43, 44, 46, 47]. Ahi-1/AHI-1 also harbors 
two potential tyrosine phosphorylation sites, one within 
the  SH3  domain.  Phosphotyrosine  motifs  are  known 
to bind specifically to SH2 domains of proteins [46]. In 
addition,  several  PEST  sequences,  known  to  mediate 
protein degradation [53, 54], are located in Ahi-1/AHI-1 
protein. Moreover, the human AHI-1 contains a coiled-
coil  domain  in  its  N-terminal  region,  also  involved  in 
protein-protein interactions [55], which is entirely absent 
in the mouse and rat Ahi-1 proteins (Figure 2) [16]. Thus 
Ahi-1 has multiple features of a unique adaptor protein 
regulating specific signaling pathways. 
Ahi-1/AHI-1  expression  in  mouse  brain 
development and hematopoiesis 
Murine Ahi-1 encodes two major RNA species (5.0 
and 4.2 kb) and several shorter splice variants [16]. Both 
mouse and human Ahi-1/AHI-1 are highly expressed in 
brain and testis and have lower expression in liver, lung, 
thymus,  kidney  and  pancreas  [16,  56].  We  and  others 
have  recently  demonstrated  that  Ahi-1  transcripts are 
expressed at all stages of mouse embryo development, 
with increasing expression just prior to birth, suggesting 
that Ahi-1 expression is developmentally regulated [16, 
21, 56]. Mouse Ahi-1 mRNA in the cerebellum has its 
highest expression at E18 and P5, whereas expression in 
the cerebral cortex appears maximally at E16 and E18 
[21].  However,  the  expression  of  mouse Ahi-1  protein 
in the cerebellum is very low and is only restricted to 
Purkinje cells and cerebellar nuclei [56, 57]. Moreover, 
in  adult  human  brain  tissue,  the  highest  expression  of 
AHI-1 at both RNA and protein levels has been detected 
in cerebellum and cerebral cortex [20, 56]. The different 
cerebellum  expression  of  Ahi-1/AHI-1  in  mouse  and 
human may be due to the additional coiled-coil domain 
present  in  the  human  AHI-1  [56].  In  addition,  Ahi-1 
is also found to be abundant in the hypothalamus and 
amygdala, two important brain region whose dysfunction 
can lead to emotional and depression phenotypes [57, 58]. 
Interestingly, it has recently been reported that impaired 
Wnt-beta-catenin signaling that disrupts renal homeostasis 
leads to cystic kidney ciliopathy, as demonstrated in Ahi-1 
conditional mutant mice [59]. Ahi-1 deficiency can also 
cause defective Wnt-dependent cerebellar midline fusion 
that is critical for the development of Joubert syndrome 
[60].  In  addition, Ahi-1  is  reported  to  directly  interact 
with  Hap1,  a  huntingtin-associated  protein  involved 
in  intracellular  trafficking,  to  regulate  cerebellar  and 
brainstem development [57]. It is known that some of 
these proteins play important roles in regulation of stem 
cell  functions.  These  results  suggest  that Ahi-1/AHI-1 
interacts  with  multiple  signaling  proteins  and  plays  an 
important  role  in  regulating  normal  brain  functions  by 
interacting with molecular partners in tissue- and disease-
specific manners. 
It  has  been  shown  that  expression  of  Ahi-1/AHI-
1  is  regulated  at  multiple  stages  of  hematopoiesis  in 
a  highly  conserved  fashion  in  mice  and  humans  [17]. 
Ahi-1/AHI-1 is expressed at its highest level in the most 
primitive hematopoietic stem cells (HSC) and is rapidly Oncotarget 2011; 2:  918 - 934 922 www.impactjournals.com/oncotarget
down-regulated as cells differentiate. Interestingly, RNA 
expression of the mouse Ahi-1 gene is 5-fold higher in 
the mouse hematopoietic stem cell-enriched population 
(Sca-1+lin-)  purified  from  normal  adult  bone  marrow 
(BM) compared to the more differentiated hematopoietic 
cells (lin+). In addition, within the different lineages of 
differentiated lin+ cells, Ahi-1 transcript levels are 6- to 
7-fold  lower  in  the  granulocyte/macrophage  lineage 
compared with the T-lymphoid, erythroid and B-lymphoid 
lineages [17]. A similar pattern of down-regulated human 
AHI-1 transcript levels during normal hematopoietic cell 
differentiation  has  also  been  observed  in  normal  adult 
human BM cells, with an overall 6-fold decrease from 
the  most  primitive  lin-CD34+CD38- subset  to  the  most 
mature  lin+ CD34- cells.  In  addition,  similar  to  mouse, 
human lin+ BM cells from the granulocyte lineage showed 
significantly reduced expression of AHI-1 compared to T, 
B and erythroid cell lineages [17]. The conserved pattern 
of changes in Ahi-1/AHI-1 expression between mice and 
humans during multi-step hematopoietic cell differentiation 
suggests that Ahi-1/AHI-1 may play important roles in the 
regulation of the normal hematopoietic stem cell-renewal 
program and downstream cell differentiation events. 
Ahi-1/AHI-1 isoforms and mutations 
Ahi-1/AHI-1  is  subject  to  alternative  splicing  and 
both murine and human Ahi-1/AHI-1 genes can encode 
at least three isoforms (Figure 2). Notably, isoform II, 
the shortest AHI-1 isoform, lacks the SH3 domain and 
isoform  III  contains  additional  coding  sequences  not 
present  in  isoform  I  or  II  [16].  Comparative  genetic 
analysis  of  the  evolution  of  the  human  AHI-1 gene 
indicates that it has undergone positive selection during 
development of the human species [20]. Thus, changes in 
AHI-1 are likely to have been important in the evolution of 
human-specific characteristics; these may include features 
of  the  mechanisms  regulating  early  stages  of  normal 
hematopoietic cell differentiation. 
Involvement  of  Ahi-1  in  mouse  models  of 
leukemogenesis  is  suggested  by  the  high  frequency  of 
Ahi-1 mutations observed in certain virus-induced murine 
lymphomas [16]. Gene-expression analyses of pre-B and 
T-cell  leukemic  cells  with  insertional  Ahi-1  mutations 
has shown both increased expression of Ahi-1 and Ahi-
1/viral fused transcripts in the malignant cells, including 
deletions of the SH3 domain in some cases [16]. Recently, 
mutations in the human AHI-1 gene have been found to be 
associated with Joubert syndrome, an autosomal recessive 
brain disorder [20-22]. Abnormal cerebellar development 
and axonal decussation were found in individuals with 
point mutations in AHI-1. These mutations generate stop 
codons,  or  amino  acid  substitutions,  or  splicing  errors 
within the AHI-1 protein. Truncating mutations are the 
most  frequent  type  (80%)  that  abolish  completely,  or 
partially,  two  critical  domains  of AHI-1: WD40-repeat 
and SH3 [22]. Altered AHI-1 isoforms and its mutations 
also underline other diseases, including Joubert syndrome-
associated  nephronophthisis  and  autism,  and  metabolic 
syndromes [18, 19, 22, 24-27]. Therefore, it is very likely 
that truncated forms of AHI-1 are critical in development 
of diseases such as Joubert syndrome and specific types of 
human leukemia. 
BIOLOGICAL FUNCTIONS OF AHI-1 IN 
HUMAN T-CELL LYMPHOMAS 
Deregulated  expression  of  AHI-1  in  human 
cutaneous T-cell lymphoma cells 
The first evidence that AHI-1 may be involved in the 
regulation of human leukemia and lymphoma development 
is based on an interesting observation that AHI-1 transcripts 
are significantly higher in a broad spectrum of established 
human leukemic and lymphoid cell lines, compared to 
normal human BM. The highest expression level is in two 
cutaneous  T-cell  lymphoma  (CTCL)  cell  lines,  Hut78, 
derived  from  a  blood  sample  of  a  patient  with  Sezary 
Syndrome (SS), and Hut102, derived from the blood of a 
patient with mycosis fungoides (MF), where increases in 
AHI-1 transcripts of 40-fold have been detected compared 
to normal BM [17]. CTCL is a heterogeneous group of 
T-cell  lymphomas  that  are  characterized  by  malignant 
T-cells that infiltrate the skin. SS and MF are two major 
subtypes of CTCL which together account for more than 
70% of all CTCL cases [61-64]. SS is the leukemic form of 
CTCL and is characterized by erythroderma, generalized 
lymphadenopathy and the presence of malignant mature 
memory  T-helper  cells  (CD4+CD7-CD45RO+),  called 
Sezary cells, in the skin, lymph nodes and peripheral blood 
[64-66]. AHI-1 is expressed at significantly higher levels 
at both RNA and protein levels in primary Sezary cells 
(CD4+CD7-) from patients with SS compared to normal 
CD4+ T-cells from normal controls [18, 24]. Particularly, 
AHI-1  isoform  II,  lacking  the  SH3  domain,  shows  the 
highest expression in SS samples compared to controls 
[18, 24]. Little is known about the molecular pathways 
involved  in  the  development  of  CTCL;  however,  the 
marked  deregulation  of  AHI-1  in  CTCL  cell  lines  and 
primary Sezary cells suggests a potential oncogenic role 
for AHI-1 in this group of diseases. 
Evidence of an oncogenic role of AHI-1 in CTCL 
cells 
To obtain direct evidence that deregulated expression 
of  AHI-1  contributes  to  the  transformed  properties  of 
human CTCL cells, knockdown of AHI-1 expression in 
Hut78  cells  was  performed  using  retroviral-mediated Oncotarget 2011; 2:  918 - 934 923 www.impactjournals.com/oncotarget
RNA interference (RNAi). A screen of nine constructs 
that produce short hairpin AHI-1 transcripts yielded one 
that specifically inhibited AHI-1 expression in transduced 
Hut78 cells by 80%, as evaluated by quantitative real-
time  RT-PCR  (Q-RT-PCR),  Northern  and Western  blot 
analyses  [18,  24].  Hut78  cells  are  characterized  by 
several  interesting  transforming  properties,  including 
autocrine  production  of  Interleukin  (IL)-2,  IL-4  and 
tumor necrosis factor-alpha (TNF-alpha), growth factor 
independence and the ability to produce tumors in mice 
[67-70].  Interestingly,  retroviral-mediated  suppression 
of AHI-1 reduced autocrine production of IL-2, IL-4 and 
TNF-alpha in Hut78 cells by up to 85% and caused a 
significant reduction in their growth factor independence 
in semi-solid cultures (up to 10-fold) and in single-cell 
cultures (4-fold) by comparison to cells transduced with 
a  control  vector.  It  was  interesting  to  note  that  these 
phenotypes can be restored in vitro in the presence of 
all  three  growth  factors  or  IL-4  and TNF-alpha  alone, 
but not IL-2 alone, indicating that AHI-1 expression is 
important in mediating autocrine production of cytokines 
that  may  have  a  pathogenic  role  in  the  progression  of 
disease (Figure 3A). In addition, aberrant expression of 
IL-2 and TNF-alpha also occurs in primary CD4+CD7- 
Sezary  cells,  further  supporting  the  idea  that  a  multi-
factorial autocrine mechanism mediated by AHI-1 could 
be  involved  in  disease  development.  Importantly,  the 
ability of Hut78 cells to produce tumors in NOD/SCID-
Figure 3: Biological effects of AHI-1 suppression in Hut78 cells and identification of its potential cooperating genes. 
(A) The number of CFCs able to make colonies in the absence of any growth factor (-GF) is significantly lower in Hut78 cells with AHI-1 
suppression (AHI-1/sh4) compared to the empty vector control (RPG). This effect is rescued by adding the three growth factors (IL-2, IL-4 
and TNF-α) to the media. (B) Subcutaneous injection of NOD/SCID-β2m immunodeficient mice with Hut78 cells and empty vector controls 
(Hut78/RPG) results in tumor formation within 4 weeks in all injected mice. AHI-1-suppressed Hut78 cells cannot form any local tumors in 
these mice even after 20 weeks. (C) Venn diagram of differentially expressed genes from the microarray analysis selected by both Limma 
and dChip analyses. Affymetrix GeneChip microarray analysis identified several differentially expressed genes in AHI-1-suppressed cells 
compared to Hut78 and empty vector controls. Initial Limma analysis selected 283 differentially expressed probe sets, which was further 
refined to 33 with the Benjamini and Hochberg (BH) P value adjustment. (D) Protein expression of HCK (left panel) and BIN1 (right panel) 
in AHI-1-suppressed cells (sh4-bulk and sh4-clone1) compared to Hut78 and Hut78/RPG controls. The two isoforms of HCK and the 65 
kDa isoform of BIN1 show upregulation in the absence of AHI-1. (E) The mRNA expression levels of HCK (left panel) and BIN1 (right 
panel) are significantly downregulated in six SS patients (red bars) compared to five CD4+ T cell samples from normal controls (blue bars).
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beta2microglobulin-/- mice within 4 weeks was also lost 
when AHI-1 expression was suppressed (Figure 3B) [18]. 
Thus, lymphomagenic activity of Hut78 cells is somehow 
dependent on the expression of AHI-1. Taken together, 
these findings provide strong evidence of the oncogenic 
activity of AHI-1 in human T-cell lymphomagenesis; its 
deregulation may contribute to the development of human 
CTCL, including Sezary syndrome. Further studies will 
be needed to fully understand the molecular mechanisms, 
biological functions and clinical role of deregulated AHI-
1 expression in CTCL.
Identification  of  BIN1  and  HCK  as  potential 
mediators of AHI-1 in CTCL 
Microarray  analysis  using  the Affymetrix  Human 
Genome U133 plus 2.0 Arrays which contains over 47,000 
transcripts  (54,330  probes)  recently  identified  several 
differentially expressed genes that may play critical roles 
in  AHI-1-mediated  leukemic  transformation  of  human 
CTCL  cells  (Figure  3C)  [24].  Two  strong  candidates 
identified in this study are a tyrosine kinase, HCK, and 
a  tumor  suppressor,  BIN1,  which  show  upregulation 
at  both  RNA  and  protein  levels  in  AHI-1-suppressed 
CTCL cells (Figure 3D) [24]. HCK (hematopoietic cell 
kinase) is a member of the Src family tyrosine kinases 
and  its  expression  is  restricted  to  hematopoietic  cells 
with predominant expression in myeloid lineage cells and 
B lymphocytes [71]. It has been reported that HCK has 
oncogenic potential in Philadelphia chromosome-positive 
(Ph+) leukemia and lymphoma cells [71, 72], however, 
other studies also demonstrated tumor suppressor functions 
for HCK in Ph- leukemias [73-75]. In CTCL cells, changes 
in HCK protein expression and its phosphorylation were 
observed in AHI-1-suppressed or overexpressed cells, and 
suppression of activities of Src family kinases, including 
HCK, by TKI (dasatinib) treatment resulted in reduced or 
increased  growth  factor-independent  growth  of  AHI-1-
overexpressed or -suppressed cells in a dose-dependent 
fashion [24]. These results thus suggest that HCK could 
be a critical player and potential target in AHI-1-mediated 
CTCL cell transformation. 
BIN1 (bridging integrator 1) is a nucleocytoplasmic 
adaptor  protein  that  was  first  identified  through  its 
interaction  with  MYC  oncoprotein,  where  it  inhibits 
its transforming activity [76]. MYC is involved in the 
development of many cancers, where its overexpression 
is  associated  with  poor  prognosis.  BIN1  attenuation  is 
frequently described in several cancers, including lung, 
breast and prostate cancer [77-80]. Alternative splicing 
Figure 4: Schematic diagram of ubiquitous and cancer-specific isoforms of BIN1, their cellular localization and 
biological functions. Ubiquitous isoform of BIN1 is localized in the cell nucleus. It can physically interact with the c-MYC oncogene, 
inhibiting its transforming activity and increasing the caspase-independent apoptosis in cancerous cells. The cancer-specific isoform of 
BIN1, with the inclusion of exon 12A, is localized in the cytoplasm, cannot interact with c-MYC and does not have any tumor suppressor 
activity in cancerous cells. 
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can yield more than 10 isoforms of BIN1 with diverse 
patterns  of  distribution  between  tissues,  subcellular 
localization  and  protein  interactions  [76,  78,  81,  82]. 
Notably, only nuclear-localizing isoforms of BIN1 have 
tumor suppressor activities that can restrict proliferation, 
survival, and immune escape of oncogenically transformed 
cells (Figure 4) [24, 83-85]. In particular, aberrant splicing 
of a brain-specific exon (exon 12A, Figure 4) in malignant 
cells can abolish the tumor-suppressor activity of BIN1 
by interfering with MYC binding [77], which is regulated 
by phosphorylation of MYC at Ser62 [86]. It has recently 
been  documented  that  Bin1  loss  can  promote  immune 
escape in cancer by deregulating the immunomodulatory 
enzyme  indoleamine  2,  3-dioxygenase  (IDO);  IDO 
inhibitors  have  also  been  found  to  potentiate  cancer 
chemotherapy  [87].  Moreover,  it  has  been  shown  that 
Bin1 interacts with the c-ABL tyrosine kinase in an SH3-
dependent manner [88]. Similarly, AHI-1 has recently been 
found to physically interact with BCR-ABL to mediate 
malignant transformation of CML stem/progenitor cells 
[19].  Interestingly,  characterization  of  BIN1 in normal 
and leukemic hematopoietic cells has not been previously 
described; nevertheless, induced up-regulation of BIN1 is 
observed in AHI-1 suppressed cells and down-regulation 
of BIN1 is found in SS patient samples (Figure 3D &E). 
Knockdown  of  AHI-1  expression  in  CTCL  cells  can 
normalize  their  transforming  activity  and  this  effect 
seems to be associated with induction of up-regulation of 
BIN1 and down-regulation of its interacting oncoprotein, 
MYC [24]. Thus AHI-1 may directly or indirectly inhibit 
expression  of  BIN1  to  enhance  its  oncogenic  activity, 
possibly through interaction with MYC. These findings 
strongly  suggest  that  AHI-1  may  cooperate  with  BIN1 
in  the  loss  of  its  tumor  suppressor  activity  through 
its  interacting  oncoprotein  MYC  to  mediate  cellular 
proliferation and apoptosis control of human CTCL cells 
and drive human CTCL pathogenesis. 
BIOLOGICAL FUNCTIONS OF AHI-1 IN 
HUMAN CHRONIC MYELOID LEUKEMIA
Clinical challenges in the treatment of CML 
CML has long served as a paradigm for generating 
new  insights  into  the  cellular  origin,  pathogenesis  and 
improved  treatment  approaches  for  many  types  of 
human  cancer.  It  is  a  clonal,  multi-step,  multi-lineage 
myeloproliferative disease that typically evolves through 
three  distinct  stages:  chronic  phase  (CP),  accelerated 
phases (AP) and blast crisis (BC) [1, 2]. The feature that 
uniquely defines CML is a clone-specific BCR-ABL fusion 
gene  that  encodes  an  oncoprotein  with  constitutively 
elevated  tyrosine  kinase  (TK)  activity,  driving  the 
pathogenesis of the disease [4-6]. Activation of BCR-ABL 
deregulates cellular proliferation, apoptosis, and genomic 
stability of primitive CML cells through effects on multiple 
intracellular signaling pathways such as the JAK2-STAT, 
RAS and phosphatidylinositol 3-kinase (PI3K) pathways 
[5, 6].  Recognition  of  the  consistent  molecular  and 
genetic alteration of BCR-ABL in CML patients’ leukemic 
cells led to the development of TKIs with selectivity for 
the BCR-ABL kinase [4, 89, 90]. Imatinib (IM) was the 
first TKI developed and has proven effective for treatment 
of  early  phase  CML  [8-10].  However,  early  relapses, 
acquired drug resistance and persistence of leukemic stem 
cells remain significant issues in many CML patients [10, 
91, 92]. The major clinical limitations encountered with 
IM  therapy  are:  (1)  IM  must  be  given  continually  for 
many years and its discontinuation always results in rapid 
reappearance of large numbers of leukemic cells [93-96]; 
(2) Even in treated patients, 15-25% of patients in early CP 
and up 40% with AP disease will fail treatment, indicating 
a need for alternatives [10, 92, 97, 98]; and (3) Relapses 
are  frequently  associated  with  mutations  in  the  BCR-
ABL  kinase  domain  [91,  92,  99].  Dasatinib  (DA)  and 
Nilotinib (NL) are the second generation of TKIs [89, 90]. 
Initial clinical experience with both DA and NL indicates 
that they may also elicit inadequate responses and fail 
to  prevent  early  disease  progression  in  some  patients 
[100, 101]. In particular, the T315I mutation, found in 
patients with IM-resistant disease, has been shown to also 
mediate  resistance  to  DA  and  NL  [102,  103].  Clinical 
evidence  thus  suggests  that  single  agent  molecularly-
targeted therapy may not cure most patients as molecular 
remissions  are  rare.  These  observations  emphasize  the 
need for development of new agents and new strategies to 
prevent continuous development of resistant subclones in 
primitive CML cells. 
Distinct features of CML stem cells resulting in 
drug resistance 
Accumulating  evidence  indicates  that  primitive 
quiescent CML cells are relatively unresponsive to TKIs 
[104, 105]. We and others have recently discovered that 
CML stem cells are insensitive to IM, with multiple unique 
features that would be expected to promote intrinsic and 
acquired resistance to BCR-ABL-targeted therapeutics [2, 
106-109]. These include elevated BCR-ABL expression 
and TK activity (Figure 5A), deregulated expression of 
several  transporter  genes  (OCT1, ABCB1 and ABCG2) 
and a high degree of genetic instability. Thus, leukemic 
stem  cells  are  a  critical  source  of  disease  recurrence 
and  a  significant  reservoir  for  the  emergence  of  drug-
resistant subclones and it is therefore critical to identify 
other  therapies  targeting  CML  stem  cells  to  overcome 
resistance.Oncotarget 2011; 2:  918 - 934 926 www.impactjournals.com/oncotarget
Deregulated  AHI-1  expression  in  CML  stem 
cells  and  its  enhanced  transforming  activity  in 
conjunction with BCR-ABL in vitro and in vivo 
Interestingly, overexpression of either Ahi-1 or BCR-
ABL alone in a murine IL-3 dependent pro-B cell line, 
BaF3, increases proliferation and viability of these cells in 
the absence and presence of IL-3. However, overexpression 
of  both  of  these  genes  simultaneously  enhances  these 
effects  [19].  Moreover,  intravenous  injection  of  NOD/
SCID-beta2m immunodeficient mice with either Ahi-1- or 
BCR-ABL-transduced BaF3 cells causes lethal leukemia 
within 70 and 40 days, respectively (Figure 5B). However, 
leukemogenic activities of co-transduced Ahi-1 and BCR-
ABL are further enhanced, producing a shorter latency of 
26 days [19]. In addition, overexpression of either Ahi-
1 or BCR-ABL alone in primitive murine hematopoietic 
stem cells (HSC) can increase their proliferation in liquid 
media, as well as elevating the number of colonies from 
both  the  colony  forming  cell  (CFC)  assay,  an  assay 
used  to  measure  the  activity  of  progenitor  cells,  and 
the long term culture-initiating cell (LTC-IC) assay, an 
assay  for  measuring  stem  cell  activities  in vitro  [110-
112].  Importantly,  in  murine  HSCs  co-transduced  with 
Ahi-1 and BCR-ABL,  all  of  these  effects  are  enhanced 
[19].  Thus,  overexpression  of  Ahi-1/AHI-1 alone can 
transform primitive hematopoietic cells  in vitro and in 
vivo; these effects are enhanced by BCR-ABL. In addition 
to overexpression studies, stable suppression of AHI-1 by 
small interfering RNA in primary CML stem/progenitor 
cells  reduces  growth  autonomy.  Furthermore,  co-
expression of Ahi-1 in BCR-ABL inducible cells reverses 
growth deficiencies exhibited by down-regulation of BCR-
ABL and results in sustained tyrosine phosphorylation of 
BCR-ABL and enhanced activation of the JAK2/STAT5 
pathway [19]. Importantly, co-immunoprecipitation assays 
have identified a new AHI-1-BCR-ABL-JAK2 interaction 
complex at endogenous levels in CML cells [19]. JAK2 is 
known to directly interact with the C-terminus of BCR-
ABL and to be a critical target of BCR-ABL in CML 
Figure 5: Model of the targeting of the AHI-1-BCR-ABL-JAK2 complex in CML stem cells by combination treatment 
with TKI and JAK2 inhibitors. (A) Detection of increased transcript levels of AHI-1 and BCR-ABL in a CML stem cell-enriched 
population (lin-CD34+CD38-), progenitor cells (lin-CD34+CD38+) and their differentiated cells (lin+CD34-) as compared to purified normal 
bone marrow cells using Q-RT-PCR. (B) Overexpression of Ahi-1 induces a lethal leukemia in vivo and enhances the effects of BCR-ABL. 
Survival curves of NOD/SCID-β2M-/- mice injected with BaF3 cells transduced with control vector, Ahi-1, BCR-ABL and Ahi-1 plus BCR-
ABL (B/A). (C) Inhibition of colony formation in semi-solid media by Imatinib in lin-CD34+ CML progenitor cells from IM-responders, 
non-responders and blast crisis patient samples transduced with either a control vector or AHI-1/sh4 vector with suppression of AHI-1. 
(D) Schematic diagram of the AHI-1-BCR-ABL-JAK2 interaction complex that regulates constitutive activation of BCR-ABL and JAK2/
STAT5 and results in increased proliferation, survival and a reduced TKI response in CML stem and progenitor cells. Targeting both BCR-
ABL and JAK2 activities to destabilize this protein interaction complex may present a potential therapeutic option for CML.
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[113-115].  Therefore,  through  an  AHI-1-BCR-ABL-
JAK2 interaction complex, AHI-1 regulates transforming 
activities of BCR-ABL transformed cells associated with 
sustained  tyrosine  phosphorylation  of  BCR-ABL  and 
enhanced activation of JAK2/STAT5 (Figure 5D).
Regulation  of  IM  sensitivity  of  CML  stem/
progenitor cells by AHI-1 
As described above, IM is an inhibitor of the BCR-
ABL  tyrosine  kinase  and  the  first-line  therapy  for  the 
CML patients [4, 8, 9]. However, early relapses and IM-
resistance  are  two  major  problems  in  some  IM-treated 
CML patients [10]. Studies have indicated that CML stem 
cells, especially those that are in the quiescent G0 stage of 
the cell cycle, are less responsive to IM, and are therefore 
a critical target population for IM resistance [104-106]. 
Thus, identification of other therapies targeting CML stem 
cells, as well as development of complementary therapies 
that target molecular events downstream of BCR-ABL are 
two major challenges in the treatment of CML. 
There  are  several  close  biological  connections 
between AHI-1 and BCR-ABL. Both AHI-1 and BCR-ABL 
transcript levels are significantly increased in the CML stem 
cell-enriched population (lin-CD34+CD38-) as compared 
to normal BM (Figure 5A) [17, 106, 107] and AHI-1 and 
BCR-ABL transcript levels are significantly higher in CML 
stem/progenitor cells from IM-nonresponders and blast 
crisis patients compared to the same cells isolated from 
IM-responders [19]. Interestingly, the AHI-1-BCR-ABL-
JAK2 complex was reported to play a key role in regulating 
IM response/resistance in BCR-ABL-transduced cells and 
primary CML stem/progenitors. Overexpression of AHI-
1 in human K562 cells resulted in greater resistance to 
IM,  while  suppression  of  AHI-1  resulted  in  increased 
sensitivity  to  IM  [19].  Altering  AHI-1  expression  in 
K562  cells  mediates  changes  in  phosphorylation  and 
protein expression of BCR-ABL, JAK2 and STAT5, with 
enhanced activity and expression of these proteins when 
AHI-1 is overexpressed, reduced activity and expression 
when AHI-1 is suppressed, and restored effects in AHI-1 
suppressed cells with overexpression of AHI-1. Strikingly, 
suppression of AHI-1 expression in primary CML stem/
progenitor cells also resulted in increased TKI sensitivity 
(Figure 5C). Particularly, CML stem/progenitor cells from 
IM-nonresponders and blast crisis patients became more 
sensitive to TKIs when AHI-1 expression was suppressed. 
Together,  these  findings  provide  strong  evidence  that 
AHI-1-BCR-ABL-JAK2  complex  modulates  response/
resistance to TKIs in CML stem/progenitor cells (Figure 
5D). 
Interestingly, recent studies have demonstrated that 
JAK2 inhibitors (TG101209, WP1193) and a dual kinase 
inhibitor of JAK2 and ABL kinases (ON044580) induce 
apoptosis in IM-sensitive and IM-resistant CML cell lines 
[116, 117] and that treatment with TKIs in combination 
with TG101209 results in greater inhibition of CML stem 
and progenitor cells, compared to treatment with either 
TKIs or TG101209 alone or a combination of TKIs (Chen, 
DeGeer and Jiang, unpublished data). Thus, targeting both 
BCR-ABL and JAK2 in CML stem/progenitor cells will 
provide a rational strategy for improving the treatment 
outcome of CML patients (Figure 5D). 
AHI-1  IS  DISRUPTED  IN  JOUBERT 
SYNDROME AND OTHER RELATED 
BRAIN DISORDERS 
In  addition  to  the  role  of  Ahi-1/AHI-1 in the 
development  of  leukemia  and  lymphoma  in  mice  and 
humans,  studies  have  also  demonstrated  its  function 
in  brain  disorders  such  as  Joubert  syndrome  (JS)  and 
related disorders (JSRD), schizophrenia and autism [20, 
21, 118-121]. JSRD are autosomal recessive disorders, 
characterized  by  a  developmental  mid-hindbrain 
malformation.  ‘‘Molar  tooth  sign’’  is  the  characteristic 
feature on a cerebral MRI, which defines the cerebellar 
vermis  and  brainstem  anomalies  and  is  the  diagnostic 
marker  of  Joubert  syndrome  [122-125].  JSRD  is 
considered a multisystem disease, with extra-neurological 
features including retinal degeneration and cystic kidney 
disease (e.g. nephronophthisis) [126, 127].
Interestingly,  genetic  pedigree  analysis  has 
demonstrated a high linkage and association between the 
AHI-1 locus and JS, a rare autosomal recessive disorder 
characterized by abnormal brain development and mental 
retardation  [20,  21,  118].  A  high  frequency  of  AHI-1 
mutations can be identified in patients with JS, with most 
mutations being frameshift or nonsense mutations which 
result in truncated N-terminal AHI-1 or loss of the WD40-
repeat and/or SH3  domains  [20,  21].  Recently,  several 
linkage  and  association  studies  have  further  identified 
AHI-1 as a susceptibility gene for schizophrenia, a major 
neuropsychiatric  disorders  associated  with  depression 
[119-121,  128,  129].  It  is  worth  noting  that  several 
features  of  autism  spectrum  disorder  (ASD),  such  as 
deficits  in  social  behaviour,  language  dysfunction  and 
repetitive behaviours, have also been described in up to 
40% of patients with JS [130, 131]. A three-stage family-
based association study has demonstrated evidence of an 
associated haplotype in AHI-1 with ASD in a region of 
the genes that has also been associated with schizophrenia 
[25]. These findings suggest an important role for AHI1 in 
common brain disorders affecting human cognition and 
behaviour.
Despite a strong genetic association of the AHI-1 
gene with susceptibility to several neuronal diseases, the 
functions of AHI-1 in regulating normal brain development 
and disease pathogenesis remain largely unknown. It has 
recently been reported that Ahi-1 forms a stable complex Oncotarget 2011; 2:  918 - 934 928 www.impactjournals.com/oncotarget
with  huntingtin-associated  protein  1  (Hap1)  in  mouse 
brains  [57],  a  protein  which  is  important  for  neonatal 
development and involved in intracellular trafficking [23, 
132-135]. Ahi-1  and  Hap1  stabilize  each  other;  Hap1 
knockout mice display a significant reduction in Ahi-1 
expression levels, defective cerebellar development and 
abnormal axonal decussation. Similarly, suppression of 
Ahi-1 in cerebellar neurons from postnatal mouse brains 
decreases  Hap1  levels.  In  addition,  truncated  Ahi-1, 
which corresponds to the mutations in JS, prevents neurite 
outgrowth in neuronal culture and is unable to stabilize 
Hap1 [57]. Furthermore, reduction in either Ahi-1 or Hap1 
in cerebellar neurons from postnatal mouse brains reduces 
the  protein  level  of  tyrosine  kinase  receptor  B  (TrkB) 
[57],  which  is  critical  for  neuronal  differentiation  and 
brain development [136, 137]. Similarly, Ahi-1 deficiency 
in mouse brain alters TrkB signaling by promoting the 
degradation of endocytic TrkB, reducing TrkB signaling 
in neuronal cells and resulting in depressive phenotypes, 
which  can  be  alleviated  with  antidepressant  drugs  or 
by overexpression of TrkB in the amygdala [58]. These 
results  provide  evidence  for  the  involvement  of  Ahi-1 
deficiency in depression, which occurs in JSRD and has 
been found to be associated with the AHI-1 gene locus. 
JSRD has additional neurological features, such as 
nephronophthisis  and  retinal  degeneration  [126,  127]. 
Ahi-1-null mice with complete loss of the Ahi-1 protein 
have normal embryonic development; however, the mice 
show postnatal runting and the majority do not survive to 
adulthood [59, 138]. The brain morphology of these mice 
is highly preserved, suggesting that other effects outside 
of the nervous system influence the survival of these mice 
[138]. One study has demonstrated the development of 
the cystic kidney disease nephronophthisis as a potential 
cause  of  death  in  Ahi-1-null  mice  [59].  Furthermore, 
mouse  models  with  conditional  Ahi-1  knockout  in  the 
kidneys have demonstrated a significant decrease in basal 
Wnt activity [59]. The Wnt signalling pathway functions 
in a broad array of cellular processes, and mutations in 
this pathway have been identified in variety of diseases, 
from  developmental  disorders  to  cancer  [139,  140].  In 
addition, Wnt activity is upregulated in mouse renal injury, 
suggesting  its  potential  role  in  adult  renal  homeostatic 
injury  repair  [141].  Interestingly,  Ahi-1  interacts  with 
beta-catenin, an integral component in the Wnt signaling 
pathway, and facilitates its translocation and accumulation 
in  the  nucleus,  resulting  in  positive  modulation  of 
downstream transcription [59]. In vivo studies have shown 
that Ahi-1 is also required for the Wnt response to injury 
and renal tubule repair, a function that is abrogated in Ahi-
1-knockout kidneys, leading to renal cystogenesis [59]. 
Moreover,  other  studies  have  demonstrated  that  Ahi-1 
knockout mice fail to form photoreceptor sensory cilia and 
photoreceptor outer segments. The retinal degeneration 
in Ahi-1 knockout mice resembles the retinal phenotype 
observed in patients with JSRD [138, 142]. In summary, 
the use of Ahi-1-deficient mouse models has facilitated 
our understanding of the molecular mechanisms and the 
pathogenesis  of  JS  and  its  related  JSRD,  and  enabled 
identification  of  potential  Ahi-1/AHI-1  interacting 
proteins critical in the development of these diseases. 
CONCLUSION
The  discovery  of  ABL  tyrosine  kinase  inhibitors 
has marked a major advance in the cancer therapy field. 
It has provided an excellent example of how a specific 
molecular abnormality can be targeted therapeutically to 
transform  a  life-threatening  malignancy  into  a  chronic 
disease. However, TKI therapy is not curative and does not 
eliminate leukemia stem cells, which remain a potential of 
relapse. Resistance to single TKI therapy is increasingly 
being  recognized,  and  more  effective  strategies  using 
combination therapies are needed to combat the 
emergence of disease resistance by effectively eradicating 
leukemic stem cells. Understanding the unique biological 
properties of cancer stem cells and identifying oncogenes 
and tumor suppressors and the molecular networks that 
regulate these properties continue to provide new insights 
into the complex processes of malignant transformation 
and  disease  progression  and  to  uncover  improved 
therapeutic  options  to  eradicate  these  critical  cells  and 
develop molecular cures. Additional insights of broader 
applicability and benefit will also be forthcoming from 
such studies. 
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